[ad_1]
[앵커]
The European Medicines Agency’EMA ‘determined that there was no link between the AstraZeneca vaccine and increased risk of blood clots. The government said it would conduct an assessment related to blood clots next week, including the EMA ruling, but said vaccination would proceed as planned. This is reporter Hyungwon Lee. The EMA of the European Medicines Agency has concluded that the AstraZeneca vaccine is not related to an increased risk of blood clots. However, I have put a long hint here. He referred to very rare cases of blood clots related to thrombocytopenia and emphasized that the investigation must continue. Women younger than 50 years had more cases of cerebral vein thrombosis or disseminated intravascular coagulation than usual. This uniqueness has not been identified in the elderly. Of course, the relevance of the vaccine in such a specific case has not even been confirmed. Caution is required before and after vaccination. If certain symptoms develop after receiving the AstraZeneca vaccine, a hospital visit is recommended. The government has a policy to proceed with vaccination as planned. Starting next week, people 65 and older in nursing hospitals and nursing facilities will receive the AstraZeneca vaccine. There is no change in judgment that vaccinating the elderly who are vulnerable to Corona 19 infection is the highest priority. As a result of confirmation from some local governments, the consent rate was found to be low, with only 50% of patients in nursing hospitals consenting to vaccination. To ease vaccination anxiety, the government will end causation for vaccines and blood clots on the 22nd after expert discussions based on the EMA’s assessment. YTN Hyungwon Lee[[email protected]]is. ※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr